Chart-Typ:
Zeitraum:
| Enlivex Ltd.: Enlivex Treasury Portfolio Update: NAV Per Ordinary Share $66.16; Total Treasury Holdings Valued at Approximately $1.1 Billion | - As of July 18, 2026, net asset value (NAV1) per share was $66.16 - As of July 18, 2026, Enlivex held 79,550,593,122 RAIN tokens with a total value of approximately $1.1 billion2- Nes-Ziona... ► Artikel lesen |
| Enlivex Ltd.: Enlivex Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Allocetra in Age-Related Knee Osteoarthritis | FDA grant of RMAT designation to Allocetra reinforces the potential of this program to deliver a meaningful, disease-modifying impact in age-related primary knee osteoarthritis, where patients face... ► Artikel lesen |
| XFRA 1BT: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen |
| Caribou Biosciences, Inc.: Caribou Biosciences to Evaluate Strategic Alternatives | -- Company to evaluate strategic alternatives to maximize stockholder value -- -- Caribou plans to discontinue vispa-cel and CB-011 allogeneic CAR-T cell therapy programs -- -- Cash, cash equivalents... ► Artikel lesen |
| Caribou Biosciences, Inc.: Caribou Biosciences Reports Dose Escalation Durability Data for CB-011 at the 2026 European Hematology Association (EHA) Annual Meeting | -- Single dose of CB-011 produced deep, durable responses in heavily pretreated, BCMA-naïve patients with r/r MM: 83% CR rate, 91% MRD negativity, and 50% of patients in =CR at 15 months -- -- Case... ► Artikel lesen |
| Caribou Biosciences, Inc.: Caribou Biosciences Reports Long-Term Vispa-cel Data in Second-line Large B Cell Lymphoma at EHA 2026 | -- Single dose of vispa-cel produced durable responses in 2L LBCL patients: 82% ORR, 67% CR rate, and 17.1-month mPFS -- -- Generally well-tolerated safety profile continues to support outpatient... ► Artikel lesen |
| Morning Market Movers: Focus Universal, CEA Industries, bioAffinity Technologies, Dyne Therapeutics See Big Swings | OTTAWA (dpa-AFX) - At 8:55 a.m. ET on Tuesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
| Morning Market Movers: Ultragenyx Pharmaceutical, bioAffinity Technologies, Tilly's, Inc., Snowflake See Big Swings | BEIJING (dpa-AFX) - At 7:50 a.m. ET on Thursday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen |
| 6 After-Hours Healthcare Gainers: Universe Pharma, BioAffinity, Modular Medical, Telix Pharma & More | BEIJING (dpa-AFX) - Today's after-hours gainers in the healthcare sector included Universe Pharmaceuticals, which drew attention after disclosing multiple Schedule 13G filings; bioAffinity Technologies... ► Artikel lesen |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ELUTIA INC finden Sie auf Wallstreet Online.